Franca S Angeli
Overview
Explore the profile of Franca S Angeli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yun S, Palladini G, Anderson L, Cariou E, Wang R, Angeli F, et al.
Amyloid
. 2024 Sep;
31(4):291-301.
PMID: 39245873
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed cause of heart failure (HF). Methods: This epidemiology study assessed the international prevalence of ATTR-CM among patients aged ≥60 years with a...
2.
Garcia-Pavia P, Lakdawala N, Sinagra G, Ripoll-Vera T, Afshar K, Priori S, et al.
ESC Heart Fail
. 2024 Aug;
11(6):4201-4208.
PMID: 39145700
Aims: LMNA-related dilated cardiomyopathy (DCM) is a rare disease with an incompletely defined phenotype. The phase 3 REALM-DCM trial evaluated a potential disease-modifying therapy for LMNA-related DCM but was terminated...
3.
Ababio Y, Kelly S, Angeli F, Berghout J, Huang K, Liu K, et al.
Am J Med Open
. 2024 Jul;
10:100038.
PMID: 39035243
Background: Dilated cardiomyopathy (DCM) contributes significantly to heart failure prevalence, yet supporting epidemiologic data is sparse. This study sought to estimate the period prevalence of DCM and the proportion of...
4.
Garcia-Pavia P, Palomares J, Sinagra G, Barriales-Villa R, Lakdawala N, Gottlieb R, et al.
Circ Heart Fail
. 2024 Jul;
17(7):e011548.
PMID: 38979608
Background: ()-related dilated cardiomyopathy is a rare genetic cause of heart failure. In a phase 2 trial and long-term extension, the selective p38α MAPK (mitogen-activated protein kinase) inhibitor, ARRY-371797 (PF-07265803),...
5.
Drachman B, Damy T, Hanna M, Wang R, Angeli F, Garcia-Pavia P
Eur J Heart Fail
. 2024 Jun;
26(9):2038-2046.
PMID: 38932583
Aims: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) present with diverse left ventricular ejection fraction (LVEF). This study assessed tafamidis efficacy by baseline LVEF in the phase 3 Tafamidis in Transthyretin...
6.
Judge D, Taylor M, Li H, Oliver C, Angeli F, Lee P, et al.
Future Cardiol
. 2023 Apr;
19(3):117-126.
PMID: 37010012
What Is This Plain Language Summary About?: This summary explains the results of a long-term extension study on the effects of a specific medicine. A long-term extension study allows people...
7.
Elahi D, Galiatsatos P, Rabiee A, Salas-Carrillo R, Vakilipour A, Carlson O, et al.
Surg Obes Relat Dis
. 2014 Dec;
10(6):1028-39.
PMID: 25443077
Background: Bariatric surgery is the most effective treatment for the reduction of weight and resolution of type 2 diabetes mellitus (T2 DM). The objective of this study was to longitudinally...
8.
Chen M, Angeli F, Shen Y, Shannon R
Cardiovasc Diabetol
. 2014 Aug;
13:115.
PMID: 25078106
Background: We previously demonstrated that older beagles have impaired whole body and myocardial insulin responsiveness (MIR), and that glucagon-like peptide-1 (GLP-1 [7-36] amide) improves MIR in young beagles with dilated...
9.
Angeli F, Shannon R
Front Horm Res
. 2014 Jun;
43:144-57.
PMID: 24943305
As cardiovascular (CV) disease remains the major cause of mortality and morbidity in type 2 diabetes mellitus, reducing macrovascular complications has been a major target of antiglycemic therapies. Emerging evidence...
10.
Elahi D, Angeli F, Vakilipour A, Carlson O, Tomas E, Egan J, et al.
Peptides
. 2014 Jun;
59:20-4.
PMID: 24937653
We have previously demonstrated in human subjects who under euglycemic clamp conditions GLP-1(9-36)amide infusions inhibit endogenous glucose production without substantial insulinotropic effects. An earlier report indicates that GLP-1(9-36)amide is cleaved...